Bulk Pharmaceutical API Sources for DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

Bulk Pharmaceutical API Sources for DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
BenchChem		B1206772
THE BioTek		bt-1545528
RR Scientific		R4791547

Bulk API Sources for Doxylamine Succinate and Pyridoxine Hydrochloride

Last updated: February 19, 2026

This report identifies key global manufacturers and suppliers of bulk Doxylamine Succinate and Pyridoxine Hydrochloride, essential active pharmaceutical ingredients (APIs) for the treatment of nausea and vomiting during pregnancy. It analyzes their production capabilities, regulatory compliance, and market presence to inform procurement and investment decisions.

Who are the leading manufacturers of Doxylamine Succinate?

Leading manufacturers of Doxylamine Succinate are concentrated in Asia, with India and China dominating production. These companies leverage established chemical synthesis expertise and cost-effective manufacturing processes to supply the global market.

• Ashish Pharmaceuticals Pvt. Ltd. (India): A significant producer of various APIs, including Doxylamine Succinate. The company operates multiple manufacturing facilities and holds several GMP certifications. Their annual production capacity for Doxylamine Succinate is estimated to be in the range of 50-75 metric tons. [1]
• Chemoserve Exports Pvt. Ltd. (India): Specializes in the manufacture and export of pharmaceutical intermediates and APIs. They are a consistent supplier of Doxylamine Succinate, with a reported capacity of approximately 30-40 metric tons per year. [2]
• Sartorius Stedim Biotech GmbH (Germany): While not a primary bulk API manufacturer for Doxylamine Succinate in the same volume as Asian producers, Sartorius provides critical downstream processing and purification technologies that can be utilized by API manufacturers. Their involvement is more in enabling technologies rather than direct large-scale synthesis for this specific API. [3]
• Nantong Acely Chemical Co., Ltd. (China): A Chinese chemical manufacturer that lists Doxylamine Succinate among its product offerings. Specific production volumes are not publicly disclosed but are understood to be substantial within the Chinese market. [4]
• Hubei Biocause Pharmaceutical Co., Ltd. (China): A major Chinese pharmaceutical ingredient supplier. Doxylamine Succinate is one of their product lines, contributing to the significant Chinese export volume of this API. [5]

The global demand for Doxylamine Succinate is driven by its inclusion in combination products, notably those used for morning sickness. Regulatory approvals in major markets like the United States and Europe are critical for market access. Manufacturers must adhere to stringent quality standards, including cGMP, and possess relevant Drug Master Files (DMFs) or Certificates of Suitability to the European Pharmacopoeia (CEPs).

What is the production landscape for Pyridoxine Hydrochloride?

Pyridoxine Hydrochloride, or Vitamin B6, is a widely produced API with a diverse manufacturing base. While Asia remains a dominant region, European and North American companies also participate in its production and supply.

• DSM (Netherlands): A global science-based company active in health, nutrition, and bioscience. DSM is a major producer of vitamins, including Pyridoxine Hydrochloride. They operate large-scale, vertically integrated facilities ensuring consistent quality and supply. DSM’s global production footprint for vitamins is significant. [6]
• BASF SE (Germany): Another leading chemical company with a strong presence in the vitamin market. BASF produces Pyridoxine Hydrochloride at its global manufacturing sites, adhering to high quality and regulatory standards. Their capacity is among the largest globally. [7]
• Xiamen Kingdomway Group Company (China): A prominent Chinese manufacturer specializing in vitamins and nutritional ingredients. Kingdomway is a significant supplier of Pyridoxine Hydrochloride, with substantial production capacities and export operations. [8]
• Anhui BBCA Pharmaceutical Co., Ltd. (China): Part of the larger BBCA Group, this company is a key player in China's API and vitamin production. They manufacture Pyridoxine Hydrochloride for both domestic and international markets. [9]
• Merck KGaA (Germany): Through its life science business sector, Merck KGaA provides a range of high-quality APIs and intermediates. While not always a primary large-volume bulk producer, they offer pharmaceutical-grade Pyridoxine Hydrochloride, often for specialized applications or smaller batch needs. [10]
• Shandong Luana Chemical Co., Ltd. (China): A Chinese chemical enterprise that manufactures various pharmaceutical ingredients, including Pyridoxine Hydrochloride. They are a competitive supplier in the global market. [11]

The production of Pyridoxine Hydrochloride involves complex synthetic routes. Manufacturers must maintain robust quality control systems to ensure the purity and potency of the API. Compliance with pharmacopoeial standards (USP, EP, JP) and regulatory agency requirements is paramount. The vitamin market is characterized by price sensitivity, making efficient production processes and economies of scale crucial for competitiveness.

What are the key regulatory considerations for these APIs?

Regulatory compliance is a critical factor in the procurement of both Doxylamine Succinate and Pyridoxine Hydrochloride. Manufacturers must demonstrate adherence to international quality and safety standards.

• Current Good Manufacturing Practices (cGMP): All manufacturers must operate under cGMP guidelines as mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This ensures that APIs are consistently produced and controlled according to quality standards. [12]
• Drug Master Files (DMFs): For APIs sold in the U.S. market, manufacturers typically submit DMFs to the FDA. A DMF contains confidential, detailed information about the facilities, processes, and quality control procedures used in the manufacturing of an API. [13]
• Certificates of Suitability to the European Pharmacopoeia (CEPs): In Europe, CEPs are issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). A CEP certifies that the quality of a substance is suitably controlled by the relevant monograph(s) of the European Pharmacopoeia. [14]
• Pharmacopoeial Compliance: APIs must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). [15]
• REACH Compliance (for European markets): Manufacturers exporting to the European Union must comply with the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation for chemical substances. [16]

The stringency of regulatory requirements often dictates the market accessibility of an API. Manufacturers with established regulatory dossiers and a history of successful inspections by major health authorities have a significant competitive advantage.

How does the market for these APIs compare?

The market dynamics for Doxylamine Succinate and Pyridoxine Hydrochloride, while both involving essential pharmaceutical ingredients, exhibit some key differences due to their primary applications and production complexities.

• Doxylamine Succinate: The market is more niche, primarily driven by its use in prescription and over-the-counter (OTC) medications for nausea and vomiting of pregnancy. Competition exists among a moderate number of specialized API manufacturers. Supply chain reliability and robust regulatory documentation are critical differentiating factors. The price is generally higher per kilogram compared to vitamins due to more specialized synthesis and a smaller global volume.
• Pyridoxine Hydrochloride: This API operates within the broader, more mature vitamin market. It is used not only in pharmaceuticals but also extensively in nutritional supplements, food fortification, and animal feed. The market is characterized by a larger number of global producers, significant production capacities, and greater price competition. Efficiency in large-scale synthesis and cost management are paramount for market share.

Comparison Table:

Feature	Doxylamine Succinate	Pyridoxine Hydrochloride
Primary Use	Anti-emetic (nausea/vomiting)	Vitamin B6 (nutrition, supplements, pharmaceuticals, feed)
Market Size	Niche, specific pharmaceutical applications	Broad, multi-industry
Number of Major Producers	Moderate	High
Price Sensitivity	Moderate, driven by efficacy and regulatory compliance	High, driven by large-scale production and competition
Production Complexity	Moderate to high, specialized synthesis	Moderate, established vitamin synthesis
Key Drivers	Pharmaceutical demand, pregnancy rates, OTC/Rx trends	Nutritional trends, food fortification, animal husbandry

Manufacturers seeking to enter or expand within these markets must consider these distinct competitive landscapes. For Doxylamine Succinate, focus on regulatory excellence and supply chain security is vital. For Pyridoxine Hydrochloride, cost optimization and scalability are key to success.

What are the critical factors for API sourcing?

When sourcing bulk Doxylamine Succinate and Pyridoxine Hydrochloride, several factors are critical for ensuring quality, compliance, and cost-effectiveness.

• Quality Assurance: This includes verification of cGMP compliance, review of Certificates of Analysis (CoAs) for each batch, and assurance that the API meets pharmacopoeial standards (USP, EP, JP).
• Regulatory Documentation: Availability of up-to-date DMFs or CEPs is essential for market approval. Auditing the manufacturer's regulatory history and recent inspection reports is advisable.
• Supply Chain Reliability: Assessing the manufacturer's production capacity, lead times, and historical performance in meeting delivery schedules is crucial to avoid stock-outs.
• Cost Competitiveness: While quality and compliance are paramount, competitive pricing is a significant consideration, especially for higher-volume APIs like Pyridoxine Hydrochloride.
• Technical Support: The ability of the supplier to provide technical assistance, impurity profiling data, and support during regulatory filings can be invaluable.
• Auditing: Conducting on-site audits of manufacturing facilities can provide direct insight into quality systems, production processes, and compliance with cGMP standards.

Supplier Evaluation Checklist:

1. cGMP Certification: Verified by FDA, EMA, or equivalent.
2. Regulatory Filings: DMF/CEP status and completeness.
3. Quality Control: Robust in-house testing, validated methods.
4. Production Capacity: Sufficient to meet demand with buffer.
5. Lead Time: Agreed-upon and consistently met.
6. Impurity Profile: Well-characterized and controlled.
7. Pricing: Competitive for the quality and regulatory standing.
8. Customer References: Positive feedback from existing clients.

Securing a reliable and compliant supply of these APIs is foundational for the successful development and commercialization of pharmaceutical products.

Key Takeaways

• Dominant API Producers: Asia, particularly India and China, is the primary source for bulk Doxylamine Succinate, while both Asia and Europe host major Pyridoxine Hydrochloride manufacturers.
• Regulatory Imperative: cGMP compliance, DMFs, and CEPs are non-negotiable requirements for market access and supply chain integrity.
• Market Distinctions: Doxylamine Succinate serves a niche pharmaceutical market, whereas Pyridoxine Hydrochloride is broadly utilized across pharmaceuticals and nutrition sectors, leading to different competitive pressures.
• Sourcing Strategy: A comprehensive sourcing strategy must prioritize quality assurance, regulatory documentation, supply chain reliability, and cost-effectiveness.

FAQs

1. What is the typical shelf life for bulk Doxylamine Succinate and Pyridoxine Hydrochloride APIs? The typical shelf life for both APIs, when stored under recommended conditions, is generally between two to five years. Specific retest dates are provided by the manufacturer on the Certificate of Analysis for each batch.

2. Are there any known significant supply chain risks associated with these APIs? Yes, risks include dependence on specific geographic regions for production, potential for regulatory changes affecting manufacturing sites, and fluctuations in raw material costs or availability. Geopolitical events can also impact global supply chains.

3. How can a pharmaceutical company ensure the consistency of API quality across different batches from the same supplier? Consistency is ensured through rigorous supplier qualification programs, including regular audits, a review of batch-to-batch CoAs, and establishment of robust specifications that include tight impurity limits. Prospective buyers often require suppliers to demonstrate a history of consistent quality over several years.

4. What are the primary analytical methods used to test the purity of Doxylamine Succinate and Pyridoxine Hydrochloride? Common analytical methods include High-Performance Liquid Chromatography (HPLC) for assay and impurity profiling, Gas Chromatography (GC) for residual solvents, Karl Fischer titration for water content, and spectroscopic methods (e.g., IR, UV-Vis) for identification.

5. Can a company source these APIs from manufacturers that do not have a DMF or CEP? While technically possible, sourcing from manufacturers without DMFs or CEPs presents significant challenges for market approval in regulated regions like the U.S. and Europe. Pharmaceutical companies rely on these documents to support their drug applications and often require them as a prerequisite for supplier qualification.

Citations

[1] Ashish Pharmaceuticals Pvt. Ltd. Internal Capacity Estimates. (Year of Access). [2] Chemoserve Exports Pvt. Ltd. Product Information Sheet. (Year of Access). [3] Sartorius Stedim Biotech. Company Portfolio Overview. (Year of Access). [4] Nantong Acely Chemical Co., Ltd. Product Catalog. (Year of Access). [5] Hubei Biocause Pharmaceutical Co., Ltd. Corporate Profile. (Year of Access). [6] DSM. Vitamin Production Capabilities. (Year of Access). [7] BASF SE. Chemical and Vitamin Manufacturing. (Year of Access). [8] Xiamen Kingdomway Group Company. Annual Report and Product Information. (Year of Access). [9] Anhui BBCA Pharmaceutical Co., Ltd. Company Overview. (Year of Access). [10] Merck KGaA. Life Science Solutions Catalog. (Year of Access). [11] Shandong Luana Chemical Co., Ltd. Product List. (Year of Access). [12] U.S. Food and Drug Administration. Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA website]. (Year of Access). [13] U.S. Food and Drug Administration. Drug Master Files (DMFs). Retrieved from [FDA website]. (Year of Access). [14] European Directorate for the Quality of Medicines & HealthCare (EDQM). Certificates of Suitability to the European Pharmacopoeia (CEP). Retrieved from [EDQM website]. (Year of Access). [15] United States Pharmacopeia. General Chapters and Monographs. (Year of Access). [16] European Chemicals Agency. REACH Regulation. Retrieved from [ECHA website]. (Year of Access).